Journal of Stroke & Cerebrovascular Diseases
Volume 17, Issue 1 , Pages 16-22 , January 2008

Low-dose of Statin Treatment Improves Cerebrovascular Reactivity in Patients With Ischemic Stroke: Single Photon Emission Computed Tomography Analysis

  • Masaji Murakami, MD, PhD

      Affiliations

    • Department of Neurosurgery, Kumamoto Takumadai Hospital, Kumamoto, Japan
    • Corresponding Author InformationAddress correspondence to Masaji Murakami, MD, PhD, Department of Neurosurgery, Kumamoto Takumadai Hospital, Onoue 1-14-27, Kumamoto 862-0913, Japan.
    • ,
  • Shodo Fujioka, MD, PhD

      Affiliations

    • Department of Neurosurgery, Saiseikai Kumamoto Hospital, Kumamoto, Japan
    • ,
  • Yoshifumi Hirata, MD, PhD

      Affiliations

    • Department of Neurosurgery, Kumamoto Takumadai Hospital, Kumamoto, Japan
    • ,
  • Jun-ichi Kuratsu, MD, PhD

      Affiliations

    • Department of Neurosurgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

Received 27 December 2006 ,Accepted 3 September 2007.

References 

  1. Goldstein IL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425–430
  2. Delanty N, Vaughan CJ. Vascular effects of statins in stroke. Stroke. 1997;28:2315–2320
  3. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101:207–213
  4. Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke. 1999;30:1969–1973
  5. Williams JK, Sukhova GK, Herrington EM, et al. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol. 1998;31:684–691
  6. Hess DC, Demchuk AM, Brass LM, et al. HMG-CoA reductase inhibitors (statins): A promising approach to stroke prevention. Neurology. 2000;54:790–796
  7. Endres M, Laufs U, Huang Z. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1998;95:8880–8885
  8. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J. Effects of the 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101:2711–2719
  9. Laufs U, La FV, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129–1135
  10. Lefer AM, Campball B, Shin YK, et al. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation. 1999;100:178–184
  11. Wagner AH, Kohler T, Ruckschloss U, et al. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol. 2000;20:61–69
  12. Scandinavian Simvastatin Survival Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S). Lancet. 1994;344:1383–1389
  13. The Long Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357
  14. Cholesterol and Recurrent Events Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol level. N Engl J Med. 1996;335:1001–1009
  15. Shepherd J, Cobbes SM, Ford I. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland coronary prevention study group. N Engl J Med. 1995;333:1301–1307
  16. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–559
  17. Sterzer P, Meintzschel F, Rosler A, et al. Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease. Stroke. 2001;32:2817–2820
  18. Murakami M, Yonehara T, Takaki A, et al. Evaluation of delayed appearance of acetazolamide effect in patients with chronic cerebrovascular ischemic disease: Feasibility and usefulness of SPECT method using triple injection of ECD. J Nucl Med. 2002;43:577–583
  19. Miyazaki Y, Mizuta Y, Honda K, et al. Assessment of a new noninvasive cerebral flow determination method using the brain uptake ratio of 99mTc-ECD. [in Japanese] Kaku Igaku. 1999;36:113–120
  20. Takeuchi R, Yonekura Y, Matsuda H, et al. Usefulness of a three-dimensional stereotaxic ROI template on anatomically standardized 99mTc-ECD SPECT. Eur J Nucl Med Mol Imaging. 2002;29:331–341
  21. Schwartz RG. Beyond the cholesterol profile monitoring therapeutic effectiveness of statin therapy. J Nucl Cardiol. 2001;8:445–451
  22. Sander K, Hof U, Poppert H, et al. Improved cerebral vasoreactivity after statin administration in healthy adults. J Neuroimaging. 2005;15:266–270
  23. Schmiedek P, Piepgras A, Leinsinger G, et al. Improvement of cerebrovascular reserve capacity by EC-IC arterial bypass surgery in patients with ICA occlusion and hemodynamic cerebral ischemia. J Neurosurg. 1994;81:236–244
  24. Widder B, Kleiser B, Krapf H. Course of cerebrovascular reactivity in patients with carotid artery occlusions. Stroke. 1994;25:1963–1967
  25. Yokoyama I, Murakami T, Ohtake T, et al. Reduced coronary flow reserve in familial hypercholesterolemia. J Nucl Med. 1996;37:1937–1942
  26. Yokoyama I, Ohtake T, Momomura S, et al. Reduced coronary flow reserve in hypercholesterolemic patients without overt coronary stenosis. Circulation. 1996;94:3232–3238
  27. Yokoyama I, Yonekura K, Inoue Y, et al. Long-term effect of simvastatin on improvement of impaired myocardial flow reserve in patients with familial hypercholesterolemia without gender variance. J Nucl Cardiol. 2001;8:445–451
  28. Box FM, van der Grond J, de Craen AJ, et al. Pravastatin decreases wall shear stress and blood velocity in the internal carotid artery without affecting flow volume: Results from the PROSPER MRI study. Stroke. 2007;38:1374–1376
  29. Empen K, Geiss HC, Lehrke M, et al. Effect of atorvastatin on lipid parameters, LDL subtype distribution, hemorrheological parameters and adhesion molecule concentrations in patients with hypertriglyceridemia. Nutr Metab Cardiovasc Dis. 2003;13:87–92
  30. Laufs U. Beyond lipid-lowering: Effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol. 2003;58:719–731
  31. Endres M. Statins and stroke. J Cereb Blood Flow Metab. 2005;25:1093–1110
  32. Huang PL, Huang Z, Mashimo H, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995;377:239–242
  33. Huang Z, Huang PL, Ma J, et al. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J Cereb Blood Flow Metab. 1996;16:981–987
  34. Ogasawara K, Ogawa A, Yoshimoto T. Cerebrovascular reactivity to acetazolamide and outcome in patients with symptomatic internal carotid or middle cerebral artery occlusion: A Xenon-133 single photon emission computed tomography study. Stroke. 2002;33:1857–1862
  35. Webster MW, Makaroun MS, Steed DL, et al. Compromised cerebral blood flow reactivity is a predictor of stroke in patients with symptomatic carotid artery occlusive diseases. J Vasc Surg. 1995;21:338–345

PII: S1052-3057(07)00144-9

doi: 10.1016/j.jstrokecerebrovasdis.2007.09.005

Journal of Stroke & Cerebrovascular Diseases
Volume 17, Issue 1 , Pages 16-22 , January 2008

Article Tools

* Image Usage & Resolution